JP3830098B2

JP3830098B2 - Method and apparatus for producing purified water for pharmaceuticals

Info

Publication number: JP3830098B2
Application number: JP2002241612A
Authority: JP
Inventors: 賢治樋口
Original assignee: Organo Corp
Current assignee: Organo Corp
Priority date: 2002-08-22
Filing date: 2002-08-22
Publication date: 2006-10-04
Anticipated expiration: 2022-08-22
Also published as: JP2004074109A

Description

【０００１】
【発明の属する技術分野】
本発明は、医薬品用精製水の製造方法および装置に関し、とくに、精製水の製造前に系内を効率よく殺菌できるようにした医薬品用精製水の製造方法および装置に関する。
【０００２】
【従来の技術】
たとえば日本薬局方で規定されている「常水」（通常、水道水に相当する水質グレードを有するもの、あるいはそれに準じるもの）を原水として医薬品製造用の精製水を製造する場合、現在、たとえば図１に示すような系統を備えた医薬品用精製水製造装置が使用されている。注射用水等さらに高いグレードが求められる場合には、この装置で製造された精製水に、さらに限外濾過等のプロセスを備えた２次処理が加えられている。本発明では、図１に示すような系統による医薬品用精製水の製造を対象としている。
【０００３】
図１に示す従来の医薬品用精製水製造装置は、基本的には、常水を原水として、逆浸透膜装置（以下、逆浸透をＲＯと略称することもある。）と電気再生式純水製造装置（以下、ＥＤＩと略称することもある。）の組み合わせにより精製水を製造するものである。通常の製造時には、原水１が一旦原水タンク２に貯留され、原水ポンプ３により原水加熱器４（たとえば、蒸気による熱交換器からなり、通常の製造時には原水を処理に適した温度、たとえば２５℃程度にコントロールする。）、ＲＯポンプ５を介してＲＯ膜を備えた逆浸透膜装置６により、逆浸透膜処理される。この逆浸透膜処理により、たとえばＴＯＣ（全有機体炭素量）が、要求値以下（たとえば、５００ｐｐｂ以下）に低減される。逆浸透膜処理後の水は、ＲＯ加熱器７（通常の製造時には使用されないが後述の殺菌時に使用されるもので、たとえば、蒸気による熱交換器からなる。）を通して電気再生式純水製造装置（ＥＤＩ）８に送られ、このＥＤＩ処理水９が、医薬品用精製水１０として取り出される。逆浸透膜装置６では、上述の如くＴＯＣ等を低く抑えることが可能であるが、医薬品用精製水に求められる電気伝導度を要求値以下（たとえば、１μＳ以下）に低下させることが困難であるので、これを達成するためには脱塩処理が必要になる。通常の脱塩処理装置では、ランニングコストが高い上に、電気伝導度とは別に精製水に求められる特性である生菌増殖抑制要求値（たとえば、１００ｃｆｕ／ｍＬ以下の生菌にすることが要求される。）を満たすことが一般に困難であるため、電気再生式純水製造装置８が使用されている。電気再生式純水製造装置８では、たとえば入口で数百ｃｆｕ／ｍＬ程度の生菌数を、出口では５０ｃｆｕ／ｍＬ程度あるいはそれ以下にまで低減できる。なお、図１に示す系統では、ＲＯ濃縮水、ＥＤＩ濃縮水、ＥＤＩ処理水のそれぞれの一部を原水タンク２に戻すラインが設けられている。
【０００４】
上記のような医薬品用精製水製造装置を用いて精製水を製造する際には、医薬品製造用の水であるため、通常の製造を開始する前に、系内の殺菌を行うことが義務付けられている。殺菌方法としては、６５℃以上（好ましくは、８０℃以上）の熱水を通水することにより行っている。そして、従来は、逆浸透膜装置６と電気再生式純水製造装置８は、それぞれ個別に熱水殺菌を行っている。個別に熱水殺菌を行う理由は、逆浸透膜装置６を熱水殺菌する場合には、ＲＯ膜の耐熱性としては十分あるものの、熱水透過時にはＲＯ膜の構造上、低温の通常製造時に比較して逆浸透膜装置６への供給圧力を低圧にする必要が生じ、その結果、ＲＯ膜透過水の水質が悪化し、ＥＤＩへの通水基準（たとえば、電気伝導度が１５μＳ以下）を超えてしまうので、そのまま続けてＥＤＩの殺菌処理に使用できないためである。したがって、一旦逆浸透膜装置６だけを熱水殺菌し、その後電気再生式純水製造装置８を熱水殺菌する場合には、図２に示すように、逆浸透膜装置６には常温の非加熱水を通水し、ＲＯ処理水をＲＯ加熱器７で加熱し、加熱した熱水を電気再生式純水製造装置８に供給するようにしている。電気再生式純水製造装置８を殺菌した熱水は、ＥＤＩ通過後、ＥＤＩ処理水９、ＥＤＩ濃縮水１１ともに系外にブローしている。したがって、図２に示すようにワンパス通水となり、供給水量および加熱のための蒸気を大量に使用することとなっており、殺菌処理の効率が悪いとともに、殺菌処理にかかる費用が高くなっている。
【０００５】
また、もう一つの殺菌方法として、図３に示すように、逆浸透膜装置６の後段にＲＯ水を保有できるサブタンク１２（循環タンク）を設け、電気再生式純水製造装置８との間で循環ループを構成する方法がある。循環ループ内では、循環ポンプ１３により循環される水は、循環加熱器１４（たとえば、蒸気による熱交換器からなる。）での加熱により殺菌用熱水とされ、その熱水が電気再生式純水製造装置８に供給される。この方法においては、ＥＤＩの通水基準によりＥＤＩ濃縮水を排出する必要はあるものの、ＥＤＩ出口水（ＥＤＩ処理水）を循環再利用できるため、蒸気および使用水を削減することができる。
【０００６】
しかしながら、医薬品製造用に使用される精製水の製造においては、生菌の増殖を極力抑えるために、製造装置には滞留部を極力なくすことが要求されている。上記のようなサブタンク１２を設置するシステムは、この要求に反して滞留部分を残すことになるから、生菌増殖の抑制上好ましいシステムとはいえない。生菌増殖抑制要求値は、前述の如く、たとえば１００ｃｆｕ／ｍＬ以下の生菌数として規定されてはいるものの、要求値を満足することは勿論のこと、低ければ低い程望ましい。
【０００７】
【発明が解決しようとする課題】
本発明の課題は、上記のような現状に鑑み、精製水製造装置の熱水殺菌を、より効率よく行うことができるとともに、系外へのブロー水量を低減し殺菌に使用する水量および蒸気量を減少して殺菌費用を低減でき、しかも、滞留部を有しないシステムに構成して生菌の増殖を抑制することが可能な、医薬品用精製水の製造方法および装置を提供することにある。
【０００８】
【課題を解決するための手段】
上記課題を解決するために、本発明に係る医薬品用精製水の製造方法は、原水を逆浸透膜装置および電気再生式純水製造装置をこの順に備えた系で処理して医薬品用精製水を製造する方法であって、精製水の製造を開始する前に系内を熱水により殺菌するに際し、実質的に非加熱の原水を逆浸透膜装置、電気再生式純水製造装置と順に通しその処理水を処理原水として一旦貯留し、該処理原水を加熱しつつ系内に循環させることにより系内を殺菌し、殺菌後に、処理原水の循環を停止し実質的に非加熱の原水を逆浸透膜装置、電気再生式純水製造装置と順に通して精製水を製造することを特徴とする方法からなる。ここで「実質的に非加熱の原水」とは、積極的に加熱操作を加えていない原水のことで、代表的には常温の原水のことを言う。
【０００９】
この方法においては、処理原水を一旦貯留するに際し、その一部を系外に排出できるようにしておくことが好ましい。また、処理原水を一旦貯留するときには、電気再生式純水製造装置の処理水を貯留するとともに逆浸透膜装置の濃縮水は系外に排出し、加熱した処理原水を循環させるときには、貯留されていた処理原水を循環させるとともに逆浸透膜装置の濃縮水も循環させるようにすることが好ましい。
【００１０】
処理原水の加熱は、その循環系内の１箇所にて行うことが可能であり、従来のように２箇所に加熱器を設ける必要はない。この処理原水の加熱は、たとえば逆浸透膜装置の前段で行うことができる。
【００１１】
上記殺菌後でかつ精製水の製造開始前には、実質的に非加熱の原水を逆浸透膜装置に通しその処理水を系外に排出または処理原水の貯留部に送給することにより、系内を適切に冷却することができる。冷却後に、通常の精製水製造を開始すればよい。
【００１２】
本発明に係る医薬品用精製水の製造装置は、原水を逆浸透膜装置および電気再生式純水製造装置をこの順に備えた系で処理して医薬品用精製水を製造する装置であって、逆浸透膜装置、電気再生式純水製造装置と順に通された処理水を処理原水として一旦貯留可能な処理原水タンクと、貯留された処理原水を前記系との間で循環可能な循環系と、該循環系内に設けられ、循環される処理原水を前記系内殺菌用の熱水とする加熱手段と、前記循環系と、前記系に精製水製造用の原水を供給する原水供給系とを切り換える切換機構とを有することを特徴とするものからなる。
【００１３】
この装置においては、処理原水タンクに、処理原水の一部を系外に排出するブローラインが接続されていることが好ましい。また、前記循環系は、電気再生式純水製造装置の処理水および濃縮水を処理原水タンクに送給するラインと、逆浸透膜装置の濃縮水の系外排出と処理原水タンクへの送給とを切り換え可能に設けられたラインとを有することが好ましい。
【００１４】
上記加熱手段としては、循環系内の１箇所のみに設けた構成とすることができる。この加熱手段は、逆浸透膜装置の前段に設けることができる。
【００１５】
また、逆浸透膜装置と電気再生式純水製造装置との間に、逆浸透膜装置の処理水を系外に排出または処理原水タンクに送給可能なラインが接続されていることが好ましい。このような構成により、熱水殺菌後の系内の冷却が可能となる。
【００１６】
【発明の実施の形態】
以下に、本発明について、望ましい実施の形態とともに、図面を参照しながら詳細に説明する。
図４は、本発明の一実施態様に係る医薬品用精製水の製造装置を示している。図４において、常水からなる原水２１は、原水供給ラインを介して送給されてくるが、このラインは、一旦原水タンク２２へ貯留するラインと、原水ポンプ２３によりそのまま原水加熱器２４（たとえば、蒸気による熱交換器）に送るラインとに分岐されており、いずれかをまたは両方を選択できるようになっている。また、原水タンク２２からは、その中に貯留されている水を原水ポンプ２３側に循環させるラインと、原水タンク２２から系外へブローするラインとに分岐されており、いずれかを選択できるようになっている。通常の精製水製造時には、常水からなる原水２１を原水ポンプ２３によりそのまま原水加熱器２４に送ることもできるし、それに加えて原水タンク２２からの水を原水加熱器２４に送ることもできる。そして、通常の精製水製造時には、供給されてきた原水は原水加熱器２４により処理に適切な温度（たとえば、２５℃程度）にコントロールされ、ＲＯポンプ２５によりＲＯ膜を備えた逆浸透膜装置２６に送られる。逆浸透膜装置２６では、ＲＯ膜により逆浸透膜処理され、ＲＯ濃縮水は一部あるいは全部が原水タンク２２に戻されるか系外にブローされ、ＲＯ透過水（ＲＯ処理水）は電気再生式純水製造装置（ＥＤＩ）２７に送られる。電気再生式純水製造装置２７からのＥＤＩ処理水２８が、医薬品用精製水２９として取り出され、ＥＤＩ濃縮水３０は原水タンク２２に戻される。ＲＯ透過水の電気再生式純水製造装置２７へのラインからは、原水タンク２２へのラインが分岐されており、ＥＤＩ処理水２８のラインからも、原水タンク２２へのラインが分岐されている。したがって、これらラインにより、原水タンク２２を介して循環系が構成されている。この循環系には、加熱手段としては上記原水加熱器２４のみが設置されており、逆浸透膜装置２６の前段に設けられている。
【００１７】
このように構成された医薬品用精製水の製造装置における、通常の精製水の製造前の殺菌処理は次のように行われる。まず、図５に示すように、系内、主として原水タンク２２内の貯留水が純水に置換される。常水からなる原水２１は、原水ポンプ２３、原水加熱器２４（非加熱）、ＲＯポンプ２５を介して逆浸透膜装置２６に送られ、ＲＯ濃縮水は系外にブローされるが、ＲＯ透過水は電気再生式純水製造装置２７に送られる。電気再生式純水製造装置２７ではＲＯ透過水を処理するので、高純度の純水が生成され、ＥＤＩ処理水２８とともにＥＤＩ濃縮水３０も原水タンク２２に送られ、純水として原水タンク２２に貯留される。なお図５においてＥＤＩ濃縮水も原水タンク２２に送られているが、ＥＤＩ濃縮水の一部または全部を図示していないブロー弁からブローし、原水タンクに送らないようにすることもできる。また、純水貯留前に原水タンク２２内に残っていた水および純水貯留開始時の水については、ブローにより原水タンク２２から系外に排出すればよい。
【００１８】
次に、一旦電気再生式純水製造装置２７を通され純水として原水タンク２２に貯留された水を用いて、熱水殺菌が行われる。図６に示すように、原水加熱器２４によって、たとえば、６５℃以上、好ましくは８０℃以上に加熱された熱水が、逆浸透膜装置２６、電気再生式純水製造装置２７、原水タンク２２と循環され、熱水により逆浸透膜装置２６および電気再生式純水製造装置２７が殺菌される。このとき、原水タンク２２に貯留されていた水は、事前に逆浸透膜装置２６、電気再生式純水製造装置２７を通した純水であるから、電気伝導度も低く、この熱水を逆浸透膜装置２６に通す際に、従来のような電気再生式純水製造装置２７への通水基準を考慮する必要がなく、したがって、逆浸透膜装置２６への供給圧力を下げる必要もない。その結果、逆浸透膜装置２６と電気再生式純水製造装置２７を個別に熱水殺菌する必要はなく、シリーズで同時に熱水殺菌可能となり、極めて効率がよい。また、図３に示したようなサブタンクを設ける必要も全くないから、滞留部を生じさせることもなく、生菌増殖を適切に抑制できる。また、殺菌用熱水を循環使用できるので、使用水量、加熱のための蒸気使用量の大幅な低減が可能となり、殺菌に要する費用も大幅に削減される。とくにこの循環される熱水の原水は、純水として原水タンク２２に貯留されたきれいな水であるから、逆浸透膜装置２６からのＲＯ濃縮水や電気再生式純水製造装置２７からのＥＤＩ濃縮水まで循環でき、使用水量、蒸気量ともに一層低減される。
【００１９】
熱水殺菌後には、通常の精製水製造に適した温度まで系を冷却し、冷却後に精製水の製造を開始するが、この冷却は、自然放冷によることも可能であるが、次のように原水を用いる方が短時間で効率よく冷却できる。
【００２０】
たとえば、図７に示すように、原水２１を原水タンク２２を通して逆浸透膜装置２６に供給し、ＲＯ濃縮水は系外にブローし、ＲＯ透過水は原水タンク２２に戻して循環することにより、まず逆浸透膜装置２６を冷却する。このとき、原水加熱器２４は、後の精製水製造に適した低温にコントロールすればよい。続いて、図８に示すように、同様にＲＯ濃縮水は系外にブローし、ＲＯ透過水を電気再生式純水製造装置２７に通水し、ＥＤＩ処理水、ＥＤＩ濃縮水ともに原水タンク２２に戻して循環することにより、電気再生式純水製造装置２７を冷却する。冷却後に、前述の如きライン構成にて、通常に精製水の製造を開始すればよい。
【００２１】
上記のような医薬品用精製水の製造方法および装置における熱水殺菌においては、逆浸透膜装置２６と電気再生式純水製造装置２７を個別に熱水殺菌しなくてもよく、かつ、加熱器も一つでよく、しかも、系外へのブローを必要最小限に止めることができることから、熱水殺菌に使用する蒸気量および水量を大幅に減少させることができる。表１に従来法との比較を示す。表１では、１０００Ｌ／ｈの精製水製造装置の場合について、本発明に係る方法、装置による使用蒸気量および水量を１とし、従来法における使用蒸気量および水量を相対量として示してある。
【００２２】
【表１】

【００２３】
また、上記のような医薬品用精製水の製造方法および装置においては、サブタンク等の滞留部がないことから、生菌の増殖も効果的に抑制できる。表２に、上記熱水殺菌を行った後、通常の精製水製造を開始した場合の、製造開始後の時間経過と生菌数との関係を確認した結果を示す。表２に示すように、電気再生式純水製造装置２７の出口、すなわち製造された医薬品用精製水には長時間生菌が全く現れず、極めて優れた殺菌効果が得られたことが確認された。
【００２４】
【表２】

【００２５】
【発明の効果】
以上説明したように、本発明に係る医薬品用精製水の製造方法および装置によれば、精製水製造装置の熱水殺菌を効率よく行うことができ、系外へのブロー水量を低減し殺菌に使用する水量および蒸気量を減少して殺菌費用を低減でき、しかも、滞留部を有しないシステムに構成して生菌の増殖を効果的に抑制することができる。
【図面の簡単な説明】
【図１】従来の医薬品用精製水の製造装置の機器系統図である。
【図２】図１の装置における熱水殺菌状態を示す機器系統図である。
【図３】従来の別の医薬品用精製水の製造装置の機器系統図である。
【図４】本発明の一実施態様に係る医薬品用精製水の製造装置の機器系統図である。
【図５】図４の装置における系内純水置換の状態を示す機器系統図である。
【図６】図４の装置における熱水殺菌状態を示す機器系統図である。
【図７】図４の装置における熱水殺菌後の逆浸透膜装置冷却の状態を示す機器系統図である。
【図８】図４の装置における熱水殺菌後の電気再生式純水製造装置冷却の状態を示す機器系統図である。
【符号の説明】
２１原水
２２原水タンク
２３原水ポンプ
２４原水加熱器
２５ＲＯポンプ
２６逆浸透膜装置
２７電気再生式純水製造装置（ＥＤＩ）
２８ＥＤＩ処理水
２９医薬品用精製水
３０ＥＤＩ濃縮水[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a method and an apparatus for producing purified water for pharmaceuticals, and more particularly to a method and an apparatus for producing purified water for pharmaceuticals that can efficiently sterilize the system before the production of purified water.
[0002]
[Prior art]
For example, when producing purified water for pharmaceutical production using “ordinary water” defined by the Japanese Pharmacopoeia (usually having a water quality grade equivalent to tap water or equivalent) as raw water, A device for producing purified water for pharmaceuticals having a system as shown in FIG. When a higher grade such as water for injection is required, a secondary treatment including a process such as ultrafiltration is further added to the purified water produced by this apparatus. The present invention is directed to the production of purified water for pharmaceuticals by the system shown in FIG.
[0003]
The conventional purified water manufacturing apparatus for pharmaceuticals shown in FIG. 1 basically uses reverse water as raw water and reverse osmosis membrane apparatus (hereinafter, reverse osmosis may be abbreviated as RO) and electrically regenerated pure water. Purified water is produced by a combination of production apparatuses (hereinafter sometimes abbreviated as EDI). During normal production, the raw water 1 is temporarily stored in the raw water tank 2, and is made up of a raw water heater 4 (for example, a heat exchanger using steam) by the raw water pump 3, and at a normal production, a temperature suitable for processing the raw water, for example, 25 ° C. The reverse osmosis membrane treatment is performed by the reverse osmosis membrane device 6 provided with the RO membrane via the RO pump 5. By this reverse osmosis membrane treatment, for example, TOC (total organic carbon content) is reduced to a required value or less (for example, 500 ppb or less). The water after the reverse osmosis membrane treatment passes through the RO heater 7 (which is not used during normal production but is used during sterilization, which will be described later, and is composed of, for example, a heat exchanger using steam). (EDI) 8 is sent to this EDI treated water 9 as pharmaceutical purified water 10. In the reverse osmosis membrane device 6, it is possible to keep TOC and the like low as described above, but it is difficult to reduce the electrical conductivity required for pharmaceutical purified water below a required value (for example, 1 μS or less). Therefore, desalting is necessary to achieve this. In a normal desalination treatment apparatus, the running cost is high, and further, it is required to make a viable cell growth suppression required value (for example, 100 cfu / mL or less) that is a characteristic required for purified water separately from electric conductivity. In general, it is difficult to satisfy the above condition, and therefore an electric regenerative pure water production apparatus 8 is used. In the electric regeneration type pure water production apparatus 8, for example, the number of viable bacteria of about several hundred cfu / mL at the inlet can be reduced to about 50 cfu / mL or less at the outlet. In addition, in the system | strain shown in FIG. 1, the line which returns each one of RO concentrated water, EDI concentrated water, and EDI treated water to the raw | natural water tank 2 is provided.
[0004]
When producing purified water using the above-mentioned purified water production equipment for pharmaceuticals, since it is water for pharmaceutical production, it is obligated to sterilize the system before starting normal production. ing. As the sterilization method, hot water of 65 ° C. or higher (preferably 80 ° C. or higher) is passed. Conventionally, the reverse osmosis membrane device 6 and the electric regenerative pure water production device 8 individually perform hot water sterilization. The reason for performing the hot water sterilization individually is that, when the reverse osmosis membrane device 6 is sterilized with hot water, the heat resistance of the RO membrane is sufficient, but the structure of the RO membrane during hot water permeation is low during normal production. In comparison, it is necessary to reduce the supply pressure to the reverse osmosis membrane device 6, and as a result, the quality of RO membrane permeated water deteriorates, and the water flow standard for EDI (for example, electric conductivity is 15 μS or less). This is because it cannot be used for sterilization of EDI. Accordingly, when only the reverse osmosis membrane device 6 is once sterilized with hot water and then the electric regenerative pure water production device 8 is sterilized with hot water, as shown in FIG. Heated water is passed, the RO-treated water is heated by the RO heater 7, and the heated hot water is supplied to the electric regenerative pure water production apparatus 8. The hot water sterilized by the electric regenerative pure water production apparatus 8 is blown out of the system together with the EDI treated water 9 and the EDI concentrated water 11 after passing through the EDI. Therefore, as shown in FIG. 2, it becomes one-pass water flow, and a large amount of supply water and steam for heating are used, and the efficiency of the sterilization treatment is low and the cost for the sterilization treatment is high. .
[0005]
As another sterilization method, as shown in FIG. 3, a sub-tank 12 (circulation tank) capable of holding RO water is provided at the rear stage of the reverse osmosis membrane device 6, and between the electric regenerative pure water production device 8. There is a way to construct a circular loop. In the circulation loop, the water circulated by the circulation pump 13 is converted into hot water for sterilization by heating in a circulation heater 14 (for example, composed of a heat exchanger using steam), and the hot water is converted into an electric regeneration type pure water. It is supplied to the water production apparatus 8. In this method, although it is necessary to discharge the EDI concentrated water according to the EDI water flow standard, the EDI outlet water (EDI treated water) can be circulated and reused, so that steam and water used can be reduced.
[0006]
However, in the production of purified water used for pharmaceutical production, in order to suppress the growth of viable bacteria as much as possible, the production apparatus is required to eliminate the stagnant portion as much as possible. The system in which the sub-tank 12 is installed as described above is not a preferable system in terms of suppressing the growth of viable bacteria, because a staying portion remains against this requirement. As described above, the viable cell growth suppression requirement value is defined as the viable cell count of 100 cfu / mL or less, for example.
[0007]
[Problems to be solved by the invention]
In view of the current situation as described above, the object of the present invention is to perform hot water sterilization of a purified water production apparatus more efficiently and reduce the amount of blow water to the outside of the system and the amount of water and steam used for sterilization. It is an object to provide a method and an apparatus for producing purified water for pharmaceuticals, which can reduce the sterilization cost by reducing the sterilization cost, and can suppress the growth of viable bacteria by constituting a system having no retention part.
[0008]
[Means for Solving the Problems]
In order to solve the above-mentioned problems, a method for producing purified water for pharmaceuticals according to the present invention comprises treating raw water with a system comprising a reverse osmosis membrane device and an electric regenerative pure water manufacturing device in this order to obtain purified pharmaceutical water. When sterilizing the system with hot water before starting the production of purified water, pass substantially unheated raw water through the reverse osmosis membrane device and the electric regenerative pure water production device in this order. The treated water is temporarily stored as treated raw water, and the treated raw water is circulated in the system while being heated, and the system is sterilized. After sterilization, the treated raw water is circulated and substantially unheated raw water is reverse osmosis. It consists of a method characterized by producing purified water through a membrane device and an electric regenerative pure water production device in this order. Here, “substantially non-heated raw water” means raw water that has not been actively heated, and typically means normal water at room temperature.
[0009]
In this method, when storing the treated raw water, it is preferable that a part of the raw water can be discharged out of the system. In addition, when temporarily storing the treated raw water, the treated water of the electric regeneration type pure water production apparatus is stored and the concentrated water of the reverse osmosis membrane apparatus is discharged out of the system, and when the heated treated raw water is circulated, it is stored. It is preferable to circulate the treated raw water and circulate the concentrated water of the reverse osmosis membrane device.
[0010]
The treatment raw water can be heated at one place in the circulation system, and there is no need to provide heaters at two places as in the prior art. This heated raw water can be heated, for example, before the reverse osmosis membrane device.
[0011]
After the sterilization and before the start of the production of purified water, the substantially unheated raw water is passed through the reverse osmosis membrane device, and the treated water is discharged out of the system or sent to the treated raw water reservoir. The inside can be cooled appropriately. After cooling, it Re to begin normal purified water production.
[0012]
An apparatus for producing purified water for pharmaceuticals according to the present invention is an apparatus for producing purified water for pharmaceuticals by treating raw water with a system comprising a reverse osmosis membrane device and an electric regenerative pure water producing device in this order. A treated raw water tank that can temporarily store treated water that has been passed through an osmosis membrane device and an electric regenerative pure water production device in order as treated raw water, and a circulating system that can circulate the stored treated raw water between the system, Heating means provided in the circulation system and using treated raw water to be circulated as hot water for sterilization in the system, the circulation system, and a raw water supply system for supplying raw water for producing purified water to the system And a switching mechanism for switching.
[0013]
In this apparatus, it is preferable that a blow line for discharging a part of the treated raw water to the outside of the system is connected to the treated raw water tank. In addition, the circulation system includes a line for supplying treated water and concentrated water of the electric regenerative pure water production apparatus to the treated raw water tank, an outflow of concentrated water from the reverse osmosis membrane apparatus, and supply to the treated raw water tank. And a line provided so as to be switchable.
[0014]
As said heating means, it can be set as the structure provided only in one place in a circulation system. This heating means can be provided upstream of the reverse osmosis membrane device.
[0015]
Moreover, it is preferable that the line which can discharge | emit the treated water of a reverse osmosis membrane apparatus out of the system, or can be supplied to a process raw | natural water tank between a reverse osmosis membrane apparatus and an electric regeneration type pure water manufacturing apparatus is connected. With such a configuration, the system can be cooled after the hot water sterilization.
[0016]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail together with preferred embodiments with reference to the drawings.
FIG. 4 shows an apparatus for producing purified water for pharmaceuticals according to one embodiment of the present invention. In FIG. 4, raw water 21 composed of normal water is fed through a raw water supply line. This line is directly stored in a raw water tank 22 and a raw water heater 24 (for example, a raw water pump 24). , Branching to a steam heat exchanger), and either or both can be selected. Further, the raw water tank 22 is branched into a line for circulating the water stored therein to the raw water pump 23 side and a line for blowing the raw water tank 22 out of the system so that either one can be selected. It has become. At the time of normal purified water production, the raw water 21 made of ordinary water can be sent directly to the raw water heater 24 by the raw water pump 23, and in addition, the water from the raw water tank 22 can be sent to the raw water heater 24. During normal purified water production, the supplied raw water is controlled by the raw water heater 24 at a temperature suitable for processing (for example, about 25 ° C.), and the RO pump 25 is provided with a reverse osmosis membrane device 26 having an RO membrane. Sent to. In the reverse osmosis membrane device 26, a reverse osmosis membrane treatment is performed by the RO membrane, and part or all of the RO concentrated water is returned to the raw water tank 22 or blown out of the system, and the RO permeated water (RO treated water) is an electric regeneration type. It is sent to a pure water production apparatus (EDI) 27. The EDI treated water 28 from the electric regenerative pure water production apparatus 27 is taken out as purified pharmaceutical water 29, and the EDI concentrated water 30 is returned to the raw water tank 22. A line to the raw water tank 22 is branched from the line to the electric regenerative pure water production apparatus 27 of the RO permeated water, and a line to the raw water tank 22 is also branched from the line of the EDI treated water 28. . Therefore, a circulation system is constituted by these lines through the raw water tank 22. In this circulation system, only the raw water heater 24 is installed as a heating means, and is provided in the front stage of the reverse osmosis membrane device 26.
[0017]
In the apparatus for producing purified water for pharmaceuticals thus configured, the sterilization treatment before the production of normal purified water is performed as follows. First, as shown in FIG. 5, the stored water in the system, mainly in the raw water tank 22, is replaced with pure water. The raw water 21 composed of normal water is sent to the reverse osmosis membrane device 26 via the raw water pump 23, the raw water heater 24 (non-heated), and the RO pump 25, and the RO concentrated water is blown out of the system, but the RO permeation is performed. Water is sent to the electric regenerative pure water production apparatus 27. Since the electric regenerative pure water production apparatus 27 processes the RO permeated water, high-purity pure water is generated, and the EDI concentrated water 30 is also sent to the raw water tank 22 together with the EDI treated water 28, and is supplied to the raw water tank 22 as pure water. Stored. In FIG. 5, the EDI concentrated water is also sent to the raw water tank 22, but part or all of the EDI concentrated water may be blown from a blow valve (not shown) so as not to be sent to the raw water tank. Further, the water remaining in the raw water tank 22 before the pure water storage and the water at the start of the pure water storage may be discharged out of the system from the raw water tank 22 by blowing.
[0018]
Next, hot water sterilization is performed using water stored in the raw water tank 22 as pure water once passed through the electric regenerative pure water production apparatus 27. As shown in FIG. 6, hot water heated to, for example, 65 ° C. or more, preferably 80 ° C. or more by the raw water heater 24 is converted into a reverse osmosis membrane device 26, an electric regenerative pure water production device 27, and a raw water tank 22. The reverse osmosis membrane device 26 and the electric regenerative pure water production device 27 are sterilized with hot water. At this time, since the water stored in the raw water tank 22 is pure water that has previously passed through the reverse osmosis membrane device 26 and the electric regenerative pure water production device 27, the electrical conductivity is low, and this hot water is reversed. When passing through the osmosis membrane device 26, it is not necessary to consider the conventional water flow standard for the electric regenerative pure water production device 27, and therefore it is not necessary to lower the supply pressure to the reverse osmosis membrane device 26. As a result, it is not necessary to individually sterilize the reverse osmosis membrane device 26 and the electric regenerative pure water production device 27 separately, and the series can be sterilized with hot water at the same time, which is extremely efficient. Moreover, since it is not necessary to provide a subtank as shown in FIG. 3, it is possible to appropriately suppress the growth of viable bacteria without causing a retention portion. Further, since the hot water for sterilization can be circulated, the amount of water used and the amount of steam used for heating can be greatly reduced, and the cost required for sterilization can be greatly reduced. In particular, since the raw hot water to be circulated is clean water stored in the raw water tank 22 as pure water, the RO concentrated water from the reverse osmosis membrane device 26 and the EDI concentration from the electric regeneration type pure water production device 27 are used. It can circulate to water, and the amount of water used and the amount of steam are further reduced.
[0019]
After the hot water sterilization, the system is cooled to a temperature suitable for ordinary purified water production, and production of purified water is started after cooling. This cooling can be performed by natural cooling. If raw water is used, it can be cooled efficiently in a short time.
[0020]
For example, as shown in FIG. 7, the raw water 21 is supplied to the reverse osmosis membrane device 26 through the raw water tank 22, the RO concentrated water is blown out of the system, and the RO permeate is returned to the raw water tank 22 and circulated. First, the reverse osmosis membrane device 26 is cooled. At this time, the raw water heater 24 may be controlled to a low temperature suitable for the subsequent production of purified water. Subsequently, as shown in FIG. 8, the RO concentrated water is similarly blown out of the system, and the RO permeated water is passed through the electric regenerative pure water production apparatus 27. Both the EDI treated water and the EDI concentrated water are supplied to the raw water tank 22. The electric regenerative pure water production apparatus 27 is cooled by circulating back to the above. After cooling, the production of purified water may be usually started with the line configuration as described above.
[0021]
In the hot water sterilization in the method and apparatus for producing purified water for pharmaceuticals as described above, the reverse osmosis membrane device 26 and the electric regenerative pure water production device 27 do not need to be individually sterilized with hot water, and the heater However, the amount of steam and the amount of water used for hot water sterilization can be greatly reduced because the blowout to the outside of the system can be minimized. Table 1 shows a comparison with the conventional method. Table 1 shows the amount of steam used and the amount of water by the method and apparatus according to the present invention as 1, and the amount of steam used and the amount of water in the conventional method as relative amounts in the case of a 1000 L / h purified water production apparatus.
[0022]
[Table 1]

[0023]
Further, in the method and apparatus for producing purified water for pharmaceuticals as described above, since there is no retention portion such as a sub tank, the growth of viable bacteria can be effectively suppressed. Table 2 shows the results of confirming the relationship between the passage of time after the start of production and the number of viable bacteria when normal purified water production is started after the hot water sterilization. As shown in Table 2, it was confirmed that no viable bacteria appeared for a long time at the outlet of the electric regenerative pure water production apparatus 27, that is, the produced purified water for pharmaceuticals, and an extremely excellent bactericidal effect was obtained. It was.
[0024]
[Table 2]

[0025]
【The invention's effect】
As described above, according to the method and apparatus for producing purified water for pharmaceuticals according to the present invention, the hot water sterilization of the purified water production apparatus can be performed efficiently, and the amount of blow water to the outside of the system can be reduced and sterilized. The amount of water and steam to be used can be reduced to reduce the sterilization cost, and the system can be configured to have no stagnation part to effectively suppress the growth of viable bacteria.
[Brief description of the drawings]
FIG. 1 is a system diagram of a conventional device for producing purified water for pharmaceuticals.
FIG. 2 is an equipment system diagram showing a hot water sterilization state in the apparatus of FIG. 1;
FIG. 3 is an equipment system diagram of another conventional apparatus for producing purified water for pharmaceutical use.
FIG. 4 is an equipment system diagram of an apparatus for producing purified water for pharmaceuticals according to one embodiment of the present invention.
5 is an equipment system diagram showing a state of in-system pure water replacement in the apparatus of FIG. 4. FIG.
6 is an equipment system diagram showing a hot water sterilization state in the apparatus of FIG. 4. FIG.
7 is an equipment system diagram showing a state of cooling of a reverse osmosis membrane device after hot water sterilization in the device of FIG.
8 is an equipment system diagram showing a state of cooling of an electric regenerative pure water producing apparatus after hot water sterilization in the apparatus of FIG.
[Explanation of symbols]
21 Raw Water 22 Raw Water Tank 23 Raw Water Pump 24 Raw Water Heater 25 RO Pump 26 Reverse Osmosis Membrane Device 27 Electric Regenerative Pure Water Production Equipment (EDI)
28 EDI treated water 29 Purified water for pharmaceuticals 30 EDI concentrated water

Claims

This is a method for producing purified water for pharmaceuticals by treating raw water in a system equipped with a reverse osmosis membrane device and an electric regeneration type pure water production device in this order. When sterilizing, the raw water, which is substantially non-heated, is passed through the reverse osmosis membrane device and the electric regeneration type pure water production device in order, and the treated water is temporarily stored as treated raw water, and the treated raw water is heated and circulated in the system By sterilizing the system, the circulation of the treated raw water is stopped after the sterilization, and the purified water is produced by passing the substantially unheated raw water through the reverse osmosis membrane device and the electric regenerative pure water production device in this order. A method for producing purified water for pharmaceuticals, which is characterized.

The method for producing purified water for pharmaceuticals according to claim 1, wherein when the treated raw water is temporarily stored, a part thereof is discharged out of the system.

When storing the treated raw water once, the treated water of the electric regenerative pure water production apparatus is stored and the concentrated water of the reverse osmosis membrane apparatus is discharged out of the system, and when the heated treated raw water is circulated, the stored treatment is stored. The method for producing purified water for pharmaceuticals according to claim 1 or 2, wherein the raw water is circulated and the concentrated water of the reverse osmosis membrane device is also circulated.

The manufacturing method of the purified water for pharmaceuticals in any one of Claims 1-3 which heats process raw | natural water at one place in the circulation system.

The manufacturing method of the purified water for pharmaceuticals of Claim 4 which heats process raw | natural water in the front | former stage of a reverse osmosis membrane apparatus.

After sterilization and before the start of production of purified water, substantially unheated raw water is passed through a reverse osmosis membrane device and the treated water is discharged out of the system or sent to the treated raw water reservoir. The manufacturing method of the purified water for pharmaceuticals in any one of Claims 1-5 which cools.

A device for producing purified water for pharmaceuticals by processing raw water in a system equipped with a reverse osmosis membrane device and an electric regenerative pure water production device in this order, and in reverse order the reverse osmosis membrane device and the electric regenerative pure water production device Treated raw water tank that can temporarily store the treated treated water as treated raw water, a circulating system that can circulate the stored treated raw water between the system, and the treated raw water that is provided and circulated in the circulating system And a switching mechanism for switching between the circulation system and a raw water supply system for supplying raw water for producing purified water to the system. Purified water production equipment.

The apparatus for producing purified water for pharmaceutical use according to claim 7, wherein a blow line for discharging a part of the treated raw water to the outside of the system is connected to the treated raw water tank.

The circulation system includes a line for supplying treated water and concentrated water of the electric regenerative pure water production apparatus to the treated raw water tank, and a discharge of the concentrated water from the reverse osmosis membrane apparatus to the treated raw water tank. The device for producing purified water for pharmaceuticals according to claim 7 or 8, comprising a line provided so as to be switchable.

The manufacturing apparatus of the purified water for pharmaceuticals in any one of Claims 7-9 with which the said heating means is provided only in one place in a circulation system.

The apparatus for producing purified water for pharmaceutical use according to claim 10, wherein the heating means is provided in the front stage of the reverse osmosis membrane apparatus.

A line capable of discharging the treated water of the reverse osmosis membrane device out of the system or feeding it to the raw water tank is connected between the reverse osmosis membrane device and the electric regenerative pure water production device. The manufacturing apparatus for the purified water for pharmaceuticals in any one of.